MannKind (NASDAQ:MNKD) PT Raised to $7 50 theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
MannKind (NASDAQ:MNKD – Get Free Report) had its price target upped by investment analysts at Cantor Fitzgerald from $6.50 to $7.50 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 41.78% from […]
MannKind (NASDAQ:MNKD – Get Free Report) had its target price upped by equities research analysts at Cantor Fitzgerald from $6.50 to $7.50 in a note issued to investors on Tuesday, Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 41.78% from […]
Shares of MannKind Co. (NASDAQ:MNKD – Get Free Report) hit a new 52-week high on Wednesday after Cantor Fitzgerald raised their price target on the stock from $6.50 to $7.50. Cantor Fitzgerald currently has an overweight rating on the stock. MannKind traded as high as $5.75 and last traded at $5.64, with a volume of […]
MannKind (NASDAQ:MNKD – Get Free Report) and Greenwich LifeSciences (NASDAQ:GLSI – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings. Valuation & Earnings This table compares MannKind and […]